Danish Business Authority's decision causes Lundbeck to downgrade guidance

Now, the Danish pharmaceutical firm Lundbeck's operational guidance for 2020 is at DKK 1.7-1.9bn (USD 275.6m-308.0m), down from DKK 2.0-2.2n. Lundbeck, however, states that its guidance for earnings before interest, taxes, depreciations and amortizations and core EBIT remain unchanged, according to a stock exchange announcement on Friday afternoon.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck steering towards weak Q4 despite Covid-19 cutbacks
For subscribers